Close

Oxford University resume Covid-19 vaccine trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...

Oxford University on Saturday, 13th Sep. 2020 announced resuming coronavirus vaccine trials, the study which was suspended following a reported side-effect in a UK patient. Oxford University, developing this vaccine with pharmaceutical company AstraZeneca confirmed the restart across all of its UK clinical trial sites after regulators gave the go-ahead following the pause on Sunday, 6th Sep. 2020.

“The independent review process has concluded and following the recommendations of both the independent safety review committee and the UK regulator, the MHRA, the trials will recommence in the UK,” it said.

With around 18,000 people received it’s vaccine so far and around 30,000 volunteers being recruited in the US, their vaccine stands as a strongest contenders among the dozens of Covid-19 vaccines in various stages of testing around the world. The restart was also welcomed by British health secretary Matt Hancock, stating in a tweet that it was “good news for everyone” and that the trial is “back up and running”. The university said in large trials such as this “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety”.

Latest stories

Related stories

CMS in US Launches WISeR Model to Enhance Original Medicare

The Centers for Medicare & Medicaid Services (CMS) is...

England GP IT Market Witnesses Shake-Up Unseen in 25 Years

England’s National Health Service, which is popularly known as...

Label Expansion In Alzheimers Gives GE HealthCare An Edge

The US Food and Drug Administration (FDA) has gone...

US Health Systems Accelerating AI Collaborations

US Health systems are speeding up their collaborations with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back